Seqens Seqens

X
[{"orgOrder":0,"company":"Cronos Group","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cronos Group and Ginkgo Bioworks Announce Achievement of THCV Equity Milestone","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed"},{"orgOrder":0,"company":"Cronos Group","sponsor":"Geocann","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cronos Group Partners with Geocann to Leverage VESIsorb Delivery Technology for Faster Absorption","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Cronos Group

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Geocann is the exclusive supplier of the VESIsorb® delivery system for cannabinoids, terpenes, and flavonoid formulations, and is well-recognized for its substantial investments in research and product development in order to meet the needs of the marketplace.

            Lead Product(s): Cannabidiol

            Therapeutic Area: Technology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Geocann

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership June 27, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Cronos has successfully achieved the productivity target for tetrahydrocannabivarin (THCV), a cannabinoid hypothesized to reduce the appetite-enhancing property of THC.

            Lead Product(s): Undisclosed

            Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Ginkgo Bioworks

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership June 21, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY